Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00087724 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00087724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00087724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2004
Completion date
September 30, 2006
Enrollment
510
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease